Endpoints at JPM23: AI in biopharma 2023 — there's no looking back

From discovery through trials, we're beyond the early stages of AI in biotech R&D. When the mission is to get to patients  faster, drug developers are increasingly looking at technology for the  answers. Beyond the initial hype, where is AI poised to make meaningful  contributions to R&D? Endpoints publisher Arsalan Arif convened a  panel of leading experts to discuss the state of AI in biotech and the  outlook for 2023. How are we getting higher quality targets into clinical  trials? How is AI playing a role in clinical trial design? What's the impact  of protein structure predicting in drug discovery? What's the outlook for AI in 2023?

‍

Moderator:

Asalan Arif, Founder & Publisher, Endpoints News

‍

Panelists:

Charles Fisher, Founder and CEO, Unlearn

Najat Khan, Chief Data Science Officer and Global Head, Strategy & Operations, R&D, The Janssen Pharmaceutical Companies of Johnson & Johnson

Alex Snyder, Chief Medical Officer, Generate Biomedicines

‍

Presented live at Endpoints at JPM 2023

Bespoke at Westfield San Francisco Centre

January 10, 2023

9:50 - 10:45am PT

‍